Research Opportunities for Medications to Treat Alcohol Dependence: Addressing Stakeholders' Needs

Alcoholism: Clinical and Experimental Research

Volumn 38, Issue 1, 2014, Pages 27-32

  Litten, Raye Z ^a   Falk, Daniel ^a   Ryan, Megan ^a   Fertig, Joanne ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcohol Medication Development; Alcohol Pharmacotherapy; Research Opportunities; Stakeholders' Needs

Indexed keywords

ACAMPROSATE; DISULFIRAM; NALTREXONE;

ALCOHOL CONSUMPTION; ALCOHOLISM; DRINKING BEHAVIOR; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; MEDICAL RESEARCH; MEDICATION COMPLIANCE; NOTE; PRIORITY JOURNAL;

ALCOHOL MEDICATION DEVELOPMENT; ALCOHOL PHARMACOTHERAPY; RESEARCH OPPORTUNITIES; STAKEHOLDERS' NEEDS;

ALCOHOL DETERRENTS; ALCOHOLISM; BIOMEDICAL RESEARCH; DRUG INDUSTRY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NALTREXONE; NARCOTIC ANTAGONISTS; TAURINE;

EID: 84892821564     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12193     Document Type: Note

References (29)

1. Boudes P (1998) Drug compliance in therapeutic trials: a review. Control Clin Trials 19:257-268.
2. Czobor P, Skolnick P (2011) The secrets of a successful clinical trial: compliance, compliance, and compliance. Mol Interv 11:107-110.
3. Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan WJ (2005) Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction 100:281-292.
4. DeVido JJ, Weiss RD (2012) Treatment of the depressed alcoholic patient. Curr Psychiatry Rep 14:610-618.
5. European Medicines Agency (2010) Guideline on the development of medicinal products for the treatment of alcohol dependence. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500074898.pdf. Accessed April 24, 2013.
6. Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, Johnson B, Stout R, Litten RZ (2010) Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res 34:2022-2034.
7. FDA (2006) Medical Review of Vivitrol. U.S. Department of Health and Human Services, Rockville, Maryland, pp 21-897.
8. Grant BF, Dawson DA (2006) The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence. Alcohol Res Health 29:79-91.
9. Heilig M, Goldman D, Berrettini W, O'Brien CP (2011) Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12:670-684.
10. IMS Health (2010) Danbury, CT. Available at: http://www.imshealth.com. Accessed
11. Johnson BA (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75:34-56.
12. Kaitin KI, Milne CP (2011) A dearth of new meds. Sci Am 305:16.
13. Kline-Simon A, Falk DE, Litten RZ, Mertens JR, Fertig J, Ryan M, Weisner CM (2013) Postreatment low-risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders. Alcohol Clin Exp Res 37(Suppl 1):E373-E380.
14. Knudsen HK, Abraham AJ, Roman PM (2011) Adoption and implementation of medications in addiction treatment programs. J Addict Med 5:21-27.
15. Levine DS (2012) Drug development: new estimate of drug development costs pegs total at $1.5 billion. The Burrill Report, December 7, San Francisco.
16. Litten RZ, Bradley AM, Moss HB (2010) Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res 34:955-967.
17. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, Falk DE, Moss H, Huebner R, Noronha A (2012) Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 17:513-527.
18. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR (2009) Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 99:345-349.
19. Mark TL, Kranzler HR, Song X (2003a) Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 71:219-228.
20. Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S (2003b) Physicians' opinions about medications to treat alcoholism. Addiction 98:617-626.
21. NIAAA (2007) Helping Patients Who Drink Too Much: A Clinician's Guide. NIH Publication No. 07-3769. NIAAA, Rockville, MD.
22. NIAAA (2009) Rethinking Drinking. NIH Publication No. 09-3770. NIAAA, Rockville, MD.
23. Oliva EM, Maisel NC, Gordon AJ, Harris AHS (2011) Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep 13:374-381.
24. O'Malley SS, O'Connor PG (2011) Medications for unhealthy alcohol use: across the spectrum. Alcohol Res Health 33:300-312.
25. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht A (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203-214.
26. Poldrugo F, Haeger D-A, Comte S, Walburg J, Palmer AJ (2005) A critical review of pharmacoeconomic studies of acamprosate. Alcohol Alcohol 40:422-430.
27. Thomas CP, Wallack SS, Lee S, McCarty D, Swift R (2003) Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat 24:1-11.
28. Thomas SE, Miller PM, Randall PK, Book SW (2008) Improving acceptance of naltrexone in community addiction treatment centers: a pilot study. J Subst Abuse Treat 35:260-268.
29. Zarkin GA, Bray JW, Aldridge A, Mitra D, Mills MJ, Couper DJ, Cisler RA (2008) Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. Arch Gen Psychiatry 65:1214-1221.